Exact Sciences Corporation (NASDAQ:EXAS) had its price objective hoisted by Bank of America Corp from $56.00 to $58.00 in a research report issued on Tuesday. The firm presently has a “buy” rating on the medical research company’s stock. Bank of America Corp’s target price indicates a potential upside of 5.47% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Vetr raised Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 price target for the company in a report on Tuesday, July 25th. Canaccord Genuity raised Exact Sciences Corporation to a “buy” rating and set a $60.00 price target for the company in a report on Tuesday. Robert W. Baird increased their price target on Exact Sciences Corporation from $49.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday. Jefferies Group LLC increased their price target on Exact Sciences Corporation to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Craig Hallum increased their price target on Exact Sciences Corporation from $46.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $49.71.

Exact Sciences Corporation (NASDAQ EXAS) traded up 9.76% during trading on Tuesday, hitting $54.99. 6,592,386 shares of the company traded hands. The firm’s market cap is $6.55 billion. The company’s 50-day moving average is $46.72 and its 200 day moving average is $38.35. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $57.95.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The firm had revenue of $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. During the same period last year, the company earned ($0.36) earnings per share. The company’s revenue for the quarter was up 158.4% on a year-over-year basis. On average, equities analysts anticipate that Exact Sciences Corporation will post ($1.17) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/31/exact-sciences-corporation-exas-price-target-raised-to-58-00.html.

In other news, SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the transaction, the senior vice president now owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Graham Peter Lidgard sold 81,025 shares of Exact Sciences Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the transaction, the insider now directly owns 366,519 shares of the company’s stock, valued at approximately $17,285,036.04. The disclosure for this sale can be found here. In the last three months, insiders sold 231,598 shares of company stock valued at $10,182,030. 4.00% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board purchased a new stake in Exact Sciences Corporation during the 2nd quarter worth about $3,006,000. Victory Capital Management Inc. purchased a new stake in Exact Sciences Corporation during the 2nd quarter worth about $29,450,000. Eagle Asset Management Inc. increased its position in Exact Sciences Corporation by 19.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,857,185 shares of the medical research company’s stock worth $65,688,000 after purchasing an additional 304,598 shares in the last quarter. Federated Investors Inc. PA increased its position in Exact Sciences Corporation by 53.3% during the 2nd quarter. Federated Investors Inc. PA now owns 34,553 shares of the medical research company’s stock worth $1,222,000 after purchasing an additional 12,018 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Exact Sciences Corporation during the 1st quarter worth about $8,298,000. 85.12% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.